Trial · NCT03176771
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 | Placebo (Double-Blind Placebo-Controlled Period) | -0.1 | 95% Confidence Interval -0.8 to 0.5 | units on a scale | |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | -2.3 | 95% Confidence Interval -3.0 to -1.7 | units on a scale | |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | -3.7 | 95% Confidence Interval -4.4 to -3.0 | units on a scale | |
| Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder) | Placebo (Double-Blind Placebo-Controlled Period) | 10.3 | percentage of AIMS responders | ||
| Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 23.9 | percentage of AIMS responders | ||
| Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 47.2 | percentage of AIMS responders | ||
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6 | Placebo (Double-Blind Placebo-Controlled Period) | -2.3 | 95% Confidence Interval -3.2 to -1.5 | units on a scale | |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6 | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | -3.8 | 95% Confidence Interval -4.7 to -3.0 | units on a scale | |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6 | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | -4.7 | 95% Confidence Interval -5.6 to -3.8 | units on a scale | |
| Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6 | Placebo (Double-Blind Placebo-Controlled Period) | 3.4 | 95% Confidence Interval 3.2 to 3.6 | units on a scale | |
| Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6 | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 3.0 | 95% Confidence Interval 2.8 to 3.3 | units on a scale | |
| Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6 | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 2.8 | 95% Confidence Interval 2.5 to 3.0 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03176771/results